| Literature DB >> 28483562 |
Lennart K A Lundblad1, Nazey Gülec2, Matthew E Poynter3, Victoria L DeVault4, Oliver Dienz5, Jonathan E Boyson6, Nirav Daphtary7, Minara Aliyeva8, Jennifer L Ather9, Felix Scheuplein10, Robert Schaub11.
Abstract
iNKT cells and mast cells have both been implicated in the syndrome of allergic asthma through their activation-induced release of Th2 type cytokines and secretion of histamine and other mediators, respectively, which can promote airways hyperresponsiveness (AHR) to agents such as methacholine. However, a mechanistic link between iNKT cells and mast cell recruitment or activation has never been explored. Our objective was to determine whether iNKT cells are necessary for the recruitment of mast cells and if iNKT cells can influence the acute allergen induced bronchoconstriction (AIB) caused by mast cell mediator release. To do so, we pharmacologically eliminated iNKT cells using a specific antibody (NKT-14) and examined its impact on airway inflammation and physiological phenotype. In mice treated with NKT-14, the elimination of iNKT cells was sufficient to prevent AHR and pulmonary eosinophilic inflammation elicited by administration of the iNKT cell agonist αGalCer. In mice treated with NKT-14 and then sensitized and challenged with house dust mite extract (HDM), eliminating the iNKT cells significantly reduced both AHR and AIB but did not affect pulmonary inflammation, the mast cell population, nor the release of the mast cell mediators mast cell protease-1 and prostaglandin D2. We conclude that while iNKT cells contribute to the phenotype of allergic airways disease through the manifestation of AIB and AHR, their presence is not required for mast cell recruitment and activation, or to generate the characteristic inflammatory response subsequent to allergen challenge.Entities:
Keywords: Airway hyperresponsiveness; Allergen induced bronchoconstriction; Antibody treatment; iNKT cell
Mesh:
Substances:
Year: 2017 PMID: 28483562 PMCID: PMC5534391 DOI: 10.1016/j.pupt.2017.05.003
Source DB: PubMed Journal: Pulm Pharmacol Ther ISSN: 1094-5539 Impact factor: 3.410